首页|广东省已上市中药制剂备案变更常见问题分析与建议

广东省已上市中药制剂备案变更常见问题分析与建议

扫码查看
目的:为我国已上市中药制剂备案变更提供指导与建议.方法:通过整理2023年广东省已上市中药制剂备案变更的受理审评情况,分析持有人申报变更存在的问题及其主要原因,从变更的事前事中事后提出可行建议.结果与结论:对213个已上市中药制剂备案变更品种进行梳理,发现持有人在备案变更方面主要存在申报程序不合规、备案内容不标准、研究验证不充分的问题.建议持有人变更前合理确立变更事项、变更时科学开展研究验证、变更后持续关注风险管理,提升中药制剂备案变更的能力.
Analysis and Suggestion on Common Problems of Post-marketing Chinese Medicine Preparation for Record Changes in Guangdong Province
Objective:To provide guidance and suggestions for the record changes of post-marketing Chinese medicine preparation in China.Methods:By sorting out the acceptance and review of the record changes of post-marketing Chinese medicine preparation in Guangdong province in 2023,the problems and main reasons of the holder's declaration of the changes were analyzed,and feasible suggestions were put forward from the events before,during and after the change.Results and Conclusion:After sorting out the 213 varieties of post-marketing Chinese medicine preparation for record changes,it was found that the holders mainly had problems in record changes such as non-compliance of the declaration procedure,the non-standard filing content,and the non-sufficient of research verification.It is suggested that the hold er should reasonably establish the changes before the change,conduct scientifically research verification during the change,continue to pay attention to risk management after the change,and improve the ability of Chinese medicine preparation record changes.

post-marketingrecord changesChinese medicine preparationcommon problemsanalytical suggestions

邓雯姬、许广宁

展开 >

广东省药品监督管理局审评认证中心,广州 510080

上市后 备案变更 中药制剂 常见问题 分析建议

2024

中国药事
中国食品药品检定研究院(中国药品生物制品检定所)

中国药事

CSTPCD
影响因子:0.844
ISSN:1002-7777
年,卷(期):2024.38(4)
  • 15